Skip to main content
Top
Published in: Endocrine 2/2022

01-05-2022 | Kidney Injury | Original Article

Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study

Authors: Qi Zhai, Jingtao Dou, Jing Wen, Meiping Wang, Yingting Zuo, Xin Su, Yibo Zhang, Herbert Gaisano, Yiming Mu, Yan He

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Purpose

To investigate whether non-high-density lipoprotein cholesterol (Non-HDL-C), remnant cholesterol (RC), and the ratios of lipid indexes are more closely associated with early progression of kidney dysfunction than traditional lipid indexes; and to explore the association between changes in serum lipids during follow-up and annual decline rate in estimated glomerular filtration rate (eGFR).

Methods

In this prospective cohort study, 3909 participants with normal eGFR and age≥40 years at baseline were followed for 3.3 years. Progression of kidney dysfunction was assessed as annual decline rate in eGFR. Spearman correlation analysis, linear correlation models, and multiple logistic regression were used to assess the associations between lipid indexes at baseline/both baseline and follow-up and the annual decline rate in eGFR.

Results

Compared with ΔLDL-C (β = 0.412), other lipid indexes such as ΔLDL-C/HDL-C (β = 0.565), ΔTC/HDL-C (β = 0.448), and ΔNon-HDL-C/HDL-C (β = 0.448) were more closely associated with annual decline rate in eGFR. High TG/HDL-C (OR = 1.699(1.177–2.454)) and TC/HDL-C (OR = 1.567(1.095–2.243)) at baseline, as well as high TC/HDL-C (OR = 1.478 (1.003–2.177)) and TG/HDL-C (OR = 1.53(1.044–2.244)) at both baseline and follow-up were associated with the annual decline rate in eGFR <0.5. High Non-HDL-C (OR = 1.633(1.025–2.602)) and LCI (OR = 1.631(1.010–2.416)) at both baseline and follow-up resulted in a 63% increase in risk of annual decline rate in eGFR >1.

Conclusion

High Non-HDL-C, RC and the ratios of lipid indexes were more closely associated with early progression of kidney injury than the increase of traditional lipid indexes. These lipid indexes should be monitored, even in participants with normal traditional serum lipid levels.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference A.S. Levey, R.T. Gansevoort, J. Coresh, L.A. Inker, H.L. Heerspink, M.E. Grams, T. Greene, H. Tighiouart, K. Matsushita, S.H. Ballew et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84–104 (2020). https://doi.org/10.1053/j.ajkd.2019.06.009CrossRefPubMed A.S. Levey, R.T. Gansevoort, J. Coresh, L.A. Inker, H.L. Heerspink, M.E. Grams, T. Greene, H. Tighiouart, K. Matsushita, S.H. Ballew et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am. J. Kidney Dis. 75, 84–104 (2020). https://​doi.​org/​10.​1053/​j.​ajkd.​2019.​06.​009CrossRefPubMed
3.
4.
go back to reference M. Rahman, W. Yang, S. Akkina, A. Alper, A.H. Anderson, L.J. Appel, J. He, D.S. Raj, J. Schelling, L. Strauss, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol 9, 1190–1198 (2014).CrossRefPubMedPubMedCentral M. Rahman, W. Yang, S. Akkina, A. Alper, A.H. Anderson, L.J. Appel, J. He, D.S. Raj, J. Schelling, L. Strauss, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin. J. Am. Soc. Nephrol 9, 1190–1198 (2014).CrossRefPubMedPubMedCentral
7.
go back to reference M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.-T. Cooney, U. Corrà, B. Cosyns, C. Deaton, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Prev. Cardiol 23, (2016) M.F. Piepoli, A.W. Hoes, S. Agewall, C. Albus, C. Brotons, A.L. Catapano, M.-T. Cooney, U. Corrà, B. Cosyns, C. Deaton, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Prev. Cardiol 23, (2016)
14.
go back to reference Joint Committee for Developing Chinese guidelines on P, Treatment of Dyslipidemia in A, Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing. Za Zhi 35, 390–419 (2007) Joint Committee for Developing Chinese guidelines on P, Treatment of Dyslipidemia in A, Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing. Za Zhi 35, 390–419 (2007)
15.
go back to reference H.I. Lim, S.J. Jun, S.W. Lee, Glomerular hyperfiltration may be a novel risk factor of restrictive spirometry pattern: analysis of the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2015. PLOS ONE 14, e0223050 (2019)CrossRefPubMedPubMedCentral H.I. Lim, S.J. Jun, S.W. Lee, Glomerular hyperfiltration may be a novel risk factor of restrictive spirometry pattern: analysis of the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2015. PLOS ONE 14, e0223050 (2019)CrossRefPubMedPubMedCentral
17.
go back to reference W.F. Keane, B.L. Kasiske, M.P. O'Donnell, Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am. J. Nephrol 8, 261–271 (1988)CrossRefPubMed W.F. Keane, B.L. Kasiske, M.P. O'Donnell, Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am. J. Nephrol 8, 261–271 (1988)CrossRefPubMed
19.
go back to reference E.S. Schaeffner, T. Kurth, G.C. Curhan, R.J. Glynn, K.M. Rexrode, C. Baigent, J.E. Buring, J.M. Gaziano, Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 14 (2003) E.S. Schaeffner, T. Kurth, G.C. Curhan, R.J. Glynn, K.M. Rexrode, C. Baigent, J.E. Buring, J.M. Gaziano, Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 14 (2003)
20.
go back to reference K. Tsuruya, H. Yoshida, M. Nagata, T. Kitazono, K. Iseki, C. Iseki, S. Fujimoto, T. Konta, T. Moriyama, K. Yamagata et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am. J. Kidney Dis. 66, 972–983 (2015). https://doi.org/10.1053/j.ajkd.2015.05.011CrossRefPubMed K. Tsuruya, H. Yoshida, M. Nagata, T. Kitazono, K. Iseki, C. Iseki, S. Fujimoto, T. Konta, T. Moriyama, K. Yamagata et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am. J. Kidney Dis. 66, 972–983 (2015). https://​doi.​org/​10.​1053/​j.​ajkd.​2015.​05.​011CrossRefPubMed
21.
go back to reference PY. Zuo, XL. Chen, YW. Liu, R. Zhang, XX. He, CY. Liu, Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease. Nutr., Metab. Cardiovasc. Dis 25, 582–587 (2015)CrossRef PY. Zuo, XL. Chen, YW. Liu, R. Zhang, XX. He, CY. Liu, Non-HDL-cholesterol to HDL-cholesterol ratio as an independent risk factor for the development of chronic kidney disease. Nutr., Metab. Cardiovasc. Dis 25, 582–587 (2015)CrossRef
23.
go back to reference Z. Yan-Bo, S. Li-Ting, W. Wei, G. Huan, Y. Handong, M. Xinwen, G. Kunquan, Y. Kun, Z. Xiaomin, H. Meian, et al., Association of blood lipid profile with incident chronic kidney disease: a Mendelian randomization study. Atherosclerosis 300, 19–25 (2020)CrossRef Z. Yan-Bo, S. Li-Ting, W. Wei, G. Huan, Y. Handong, M. Xinwen, G. Kunquan, Y. Kun, Z. Xiaomin, H. Meian, et al., Association of blood lipid profile with incident chronic kidney disease: a Mendelian randomization study. Atherosclerosis 300, 19–25 (2020)CrossRef
30.
go back to reference A.L. Catapano, I. Graham, G. De Backer, O. Wiklund, M.J. Chapman, H. Drexel, A.W. Hoes, C.S. Jennings, U. Landmesser, T.R. Pedersen et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253, 281–344 (2016). https://doi.org/10.1016/j.atherosclerosis.2016.08.018CrossRefPubMed A.L. Catapano, I. Graham, G. De Backer, O. Wiklund, M.J. Chapman, H. Drexel, A.W. Hoes, C.S. Jennings, U. Landmesser, T.R. Pedersen et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253, 281–344 (2016). https://​doi.​org/​10.​1016/​j.​atherosclerosis.​2016.​08.​018CrossRefPubMed
31.
go back to reference M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A.L. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345–1361 (2011) M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A.L. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345–1361 (2011)
32.
go back to reference D. Wadhwa, V.K. Mahajan, K.S. Mehta, P.S. Chauhan, R.S. Yadav, S. Bhushan, V. Sharma, A. Sharma, A. Sharma, Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study. Arch. Dermatol. Res 311, 287–297 (2019)CrossRefPubMed D. Wadhwa, V.K. Mahajan, K.S. Mehta, P.S. Chauhan, R.S. Yadav, S. Bhushan, V. Sharma, A. Sharma, A. Sharma, Malondialdehyde, lipoprotein-a, lipoprotein ratios, comprehensive lipid tetrad index and atherogenic index as surrogate markers for cardiovascular disease in patients with psoriasis: a case-control study. Arch. Dermatol. Res 311, 287–297 (2019)CrossRefPubMed
33.
go back to reference F.M. Sacks, M.P. Hermans, P. Fioretto, P. Valensi, T. Davis, E. Horton, C. Wanner, K. Al-Rubeaan, R. Aronson, I. Barzon et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129, 999–1008 (2014). https://doi.org/10.1161/circulationaha.113.002529CrossRefPubMed F.M. Sacks, M.P. Hermans, P. Fioretto, P. Valensi, T. Davis, E. Horton, C. Wanner, K. Al-Rubeaan, R. Aronson, I. Barzon et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129, 999–1008 (2014). https://​doi.​org/​10.​1161/​circulationaha.​113.​002529CrossRefPubMed
34.
go back to reference G.T. Russo, S. De Cosmo, F. Viazzi, A. Pacilli, A. Ceriello, S. Genovese, P. Guida, C. Giorda, D. Cucinotta, R. Pontremoli, P. Fioretto, Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative. Diabetes Care 39, 2278–2287 (2016). https://doi.org/10.2337/dc16-1246CrossRefPubMed G.T. Russo, S. De Cosmo, F. Viazzi, A. Pacilli, A. Ceriello, S. Genovese, P. Guida, C. Giorda, D. Cucinotta, R. Pontremoli, P. Fioretto, Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative. Diabetes Care 39, 2278–2287 (2016). https://​doi.​org/​10.​2337/​dc16-1246CrossRefPubMed
Metadata
Title
Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study
Authors
Qi Zhai
Jingtao Dou
Jing Wen
Meiping Wang
Yingting Zuo
Xin Su
Yibo Zhang
Herbert Gaisano
Yiming Mu
Yan He
Publication date
01-05-2022
Publisher
Springer US
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03012-z

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine